1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jiangsu Hengrui Medicine Co., Ltd.
  6. News
  7. Summary
    600276   CNE0000014W7

JIANGSU HENGRUI MEDICINE CO., LTD.

(600276)
  Report
End-of-day quote Shanghai Stock Exchange  -  05-26
29.78 CNY   +2.55%
05/11China’s Pharma Firms Post 67% Jump in Profit in 2021
MT
04/25Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 31.71 Yuan From 55.66 Yuan, Keeps at Neutral
MT
04/22Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021

10/19/2021 | 05:46am EDT

Jiangsu Hengrui Medicine Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 20,198.97 million compared to CNY 19,413.13 million a year ago. Revenue was CNY 20,198.97 million compared to CNY 19,413.13 million a year ago. Net income was CNY 4,207.2 million compared to CNY 4,258.59 million a year ago. Basic earnings per share from continuing operations was CNY 0.66 compared to CNY 0.67 a year ago. Diluted earnings per share from continuing operations was CNY 0.66 compared to CNY 0.66 a year ago.


© S&P Capital IQ 2021
All news about JIANGSU HENGRUI MEDICINE CO., LTD.
05/11China’s Pharma Firms Post 67% Jump in Profit in 2021
MT
04/25Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 31.71 Yuan From 55.66 Y..
MT
04/22Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended..
CI
03/13Jiangsu Hengrui Medicine Co., Ltd. announces an Equity Buyback for CNY 1,200 million wo..
CI
03/13Jiangsu Hengrui Medicine Co., Ltd. authorizes a Buyback Plan.
CI
2021CStone Pharma Grants Jiangsu Hengrui Rights to Investigational Cancer Drug in Greater C..
MT
2021Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended S..
CI
2021BeyondSpring Shares Up 17% After China Commercialization Deal
DJ
2021Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1..
CI
2021Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended Jun..
CI
More news
Analyst Recommendations on JIANGSU HENGRUI MEDICINE CO., LTD.
More recommendations
Financials
Sales 2022 26 575 M 3 967 M 3 967 M
Net income 2022 5 107 M 762 M 762 M
Net cash 2022 18 806 M 2 807 M 2 807 M
P/E ratio 2022 36,3x
Yield 2022 0,50%
Capitalization 190 B 28 356 M 28 356 M
EV / Sales 2022 6,44x
EV / Sales 2023 5,54x
Nbr of Employees 24 491
Free-Float 47,9%
Chart JIANGSU HENGRUI MEDICINE CO., LTD.
Duration : Period :
Jiangsu Hengrui Medicine Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JIANGSU HENGRUI MEDICINE CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 29,78 CNY
Average target price 54,75 CNY
Spread / Average Target 83,8%
EPS Revisions
Managers and Directors
Wei Dong Chairman-Supervisory Board
Piao Yang Sun Chairman
Xiao-Jing Zhang Chief Medical Officer
Shuang Xue Independent Director
Qian Wang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JIANGSU HENGRUI MEDICINE CO., LTD.-41.27%28 356
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098